Quanterix Corp  (QTRX)
Other Ticker:  
Price: $16.4200 $-0.14 -0.845%
Day's High: $16.7099 Week Perf: -4.65 %
Day's Low: $ 16.12 30 Day Perf: 5.32 %
Volume (M): 218 52 Wk High: $ 29.70
Volume (M$): $ 3,576 52 Wk Avg: $23.10
Open: $16.56 52 Wk Low: $14.26

 Market Capitalization (Millions $) 617
 Shares Outstanding (Millions) 38
 Employees 359
 Revenues (TTM) (Millions $) 122
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) -165
 Capital Exp. (TTM) (Millions $) 3

Quanterix Corp
Quanterix Corp is a biotech company that focuses on the development and commercialization of ultra-sensitive digital biomarker analysis solutions.
The company was founded in 2007 by David Walt, who is a pioneer in microarray technology.
Quanterix Corp aims to revolutionize the way diseases are detected and measured by providing accurate and precise biomarker measurements that can help diagnose and treat diseases at an earlier stage.
The company's flagship product is the Simoa system, which is a fully automated digital immunoassay platform that can detect and measure low-abundance biomolecules with unprecedented sensitivity.
Simoa uses single-molecule detection technology to accurately quantify proteins, DNA, and RNA molecules in biological samples, allowing scientists and clinicians to gain new insights into disease mechanisms and improve disease diagnosis and treatment.
Quanterix Corp's technology has a wide range of applications, including oncology, neurology, cardiology, infectious diseases, inflammation, and autoimmune diseases.
The company collaborates with leading academic institutions, pharmaceutical companies, and diagnostic companies to validate its technology and develop innovative diagnostic assays.
Quanterix Corp has received numerous awards for its technology, including being named a Technology Pioneer by the World Economic Forum, one of the 50 Smartest Companies by MIT Technology Review, and one of the Top 10 Innovations of the Year by The Scientist magazine.
The company is headquartered in Billerica, Massachusetts, and has offices and subsidiaries in Europe and Asia.

   Company Address: 900 Middlesex Turnpike Billerica 1821 MA
   Company Phone Number: 301-9400   Stock Exchange / Ticker: NASDAQ QTRX


Stock Performances by Major Competitors

5 Days Decrease / Increase
QSI   -8.47%    
• View Complete Report

Product Service News

Quanterix Unveils Partnership Path to Enhance Global Alzheimer's Disease Testing Infrastructure

Published Thu, Mar 21 2024 9:30 PM UTC

Quanterix Outlines Partner Path to Accelerate Global Alzheimer's Disease Testing InfrastructureQuanterix Corporation, a prominent provider of ultra-sensitive research products and high-definition diagnostics, recently unveiled its strategic partnership path to enable laboratories in offering Tau-based research and diagnostic testing services. The company, which holds over th...

Product Service News

Quanterix's Breakthrough Blood-Based p-Tau 217 Test Receives FDA Designation for Alzheimer's Disease Diagnosis

Published Mon, Mar 4 2024 2:00 PM UTC

Quanterix Corporation, a leading provider of ultra-sensitive research products and high-definition diagnostics, has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Simoa phospho-Tau 217 (p-Tau 217) blood test. This groundbreaking designation marks a significant achievement in the field of Alzheimer's Disease (AD) diagnostics,...


Quanterix Strikes Game-Changing Partnerships to Advance Alzheimer's Diagnosis, Competitors' Revenue Outpacing Growth

Published Mon, Feb 26 2024 2:00 PM UTC

Quanterix Corporation, a prominent provider of ultra-sensitive research products and high-definition diagnostics, has recently announced its first collaborations with five major health networks. The aim of these collaborations is to enhance the diagnosis and clinical management of individuals suffering from Alzheimer's disease (AD). By expanding clinical access to its leadin...

Quanterix Corp

Quanterix Corp Defies Expectations: Dramatic Turnaround Marks Impressive Redemption of Deficit in Fiscal Year 2023

Quanterix Corp, a leading provider of ultra-sensitive diagnostics known for its Simoa technology, has recently released its financial results for the fiscal interval ending March 31, 2023. The results showcase the company's progress, with significant improvements in both EPS and revenue generation.
In Q1 2023, Quanterix Corp decreased its loss per share to $-0.16 per share, a marked improvement from the $-0.43 loss per share in the prior year's corresponding quarter. Sequentially, the company's EPS improved from $-0.29 per share in the preceding quarter. The increase in EPS reflects the company's focus on enhancing operational efficiency and effectively utilizing its resources.


Quanterix's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Quanterix does not provide revenue guidance.

Earnings Outlook
Quanterix Corp does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com